Always up to date.
 

Our goal is to develop procedure and anatomy specific devices that lead in collaboration with our customers to predictable and superior treatment outcomes. Read on to learn more about our solutions, priorities, partnerships and how we create sustainable value with our teams.

Page 4 of 12.

Medartis has decided not to pursue the convertible bond placement

Ad hoc announcement pursuant to Art. 53 LR

Basel, 8 April 2022: The Board of Medartis has decided not to pursue the planned convertible bond placement, which was announced on Thursday evening. The...

Read more

Medartis launches senior convertible bond offering with a target size of CHF 125-150 million

Ad hoc announcement pursuant to Art. 53 LR

Basel, 7 April 2022: Medartis Holding AG (SIX: MED, the “Issuer” or “Medartis”), a specialized orthopaedic company for head and extremity surgery, announces...

Read more

Strong sales growth and further margin improvements – important acquisition to accelerate the US extremities business

  • Total net sales increased by 24.8% year-on-year at CER[1]
  • All regions grew by more than 20% CER – 29% growth in the US and 22% in EMEA
  • Strong growth led to higher margins at all levels – EBITDA...
Read more

Page 4 of 12.